Reno Debets

Rotterdam, ZH, Netherlands

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 117 publications

Publisher Correction: CLEAR-IT, a framework for contrastive learning to capture the immune composition of tumor microenvironments.

Publisher Correction: CLEAR-IT, a framework for contrastive learning to capture the immune composition of tumor microenvironments.

Journal: Communications biology
Published: July 01, 2026

In Remembrance of Professor Zelig Eshhar: A Life Committed to CAR-T.

In Remembrance of Professor Zelig Eshhar: A Life Committed to CAR-T.

Journal: Human gene therapy
Published: June 18, 2026

Blood-based kinase activity profiling to predict response to immune checkpoint inhibitors in patients with advanced stage NSCLC: the prospective IOpener study.

Blood-based kinase activity profiling to predict response to immune checkpoint inhibitors in patients with advanced stage NSCLC: the prospective IOpener study.

Journal: Journal for immunotherapy of cancer
Published: June 15, 2026

In Remembrance of Professor Zelig Eshhar: A Life Committed to CAR-T.

In Remembrance of Professor Zelig Eshhar: A Life Committed to CAR-T.

Journal: Human gene therapy
Published: March 28, 2026

Molecular profile of residual triple-negative breast cancer: opportunities for post-neoadjuvant therapeutic interventions.

Molecular profile of residual triple-negative breast cancer: opportunities for post-neoadjuvant therapeutic interventions.

Journal: NPJ breast cancer
Published: November 27, 2025

HYpofractionated, dose-redistributed RAdiotherapy (HYDRA) versus conventional radiotherapy for head and neck cancer: planned interim analysis and dosimetric comparison from the phase I HYDRA trial.

HYpofractionated, dose-redistributed RAdiotherapy (HYDRA) versus conventional radiotherapy for head and neck cancer: planned interim analysis and dosimetric comparison from the phase I HYDRA trial.

Journal: Clinical and translational radiation oncology
Published: November 07, 2025

A multigene model for response stratification to neoadjuvant chemotherapy in triple negative breast cancer.

A multigene model for response stratification to neoadjuvant chemotherapy in triple negative breast cancer.

Journal: Breast (Edinburgh, Scotland)
Published: October 03, 2025

Multivalent Atezolizumab-Liposome Conjugates as Active Immunotherapeutic Platforms for Enhanced PD-L1 Blockade in Melanoma.

Multivalent Atezolizumab-Liposome Conjugates as Active Immunotherapeutic Platforms for Enhanced PD-L1 Blockade in Melanoma.

Journal: International journal of nanomedicine
Published: August 16, 2025

Long-term survivors of melanoma after anti-PD-1 therapy demonstrate on-treatment increase in abundance of 4-1BB+ CD4 T cells in blood.

Long-term survivors of melanoma after anti-PD-1 therapy demonstrate on-treatment increase in abundance of 4-1BB+ CD4 T cells in blood.

Journal: Journal of immunology (Baltimore, Md. : 1950)
Published: July 31, 2025

Tumor-associated macrophages: untapped molecular targets to improve T cell-based immunotherapy.

Tumor-associated macrophages: untapped molecular targets to improve T cell-based immunotherapy.

Journal: Molecular cancer
Published: July 16, 2025

A roadmap for supporting the development of advanced therapy medicinal products in a European framework.

A roadmap for supporting the development of advanced therapy medicinal products in a European framework.

Journal: The Lancet regional health. Europe
Published: July 03, 2025

T cell immunity in glioma and potential implications for immunotherapy: a systematic review.

T cell immunity in glioma and potential implications for immunotherapy: a systematic review.

Journal: Neuro-oncology
Published: July 01, 2025
Showing 1-12 of 117

Last Updated: 09/26/2026